Is It Normal to Feel Tired When Starting Wegovy?

Feeling unusually tired during the first weeks of Wegovy treatment can happen. Fatigue is a reported side effect of semaglutide, the active ingredient in Wegovy and Ozempic, and some people notice it most during the dose-escalation phase. However, tiredness is not something you have to simply push through: it can also reflect eating or drinking too little, changes in blood sugar, another medication, or an unrelated health issue.

If you have started Wegovy and your energy has dipped, the pattern, severity, and other symptoms matter. This guide explains what may be behind early fatigue, what research can—and cannot—tell us, and how to look after your health and training capacity while you and your prescriber assess what is happening.

Why can Wegovy make you feel tired?

Wegovy contains semaglutide, a glucagon-like peptide-1 receptor agonist, often shortened to GLP-1 RA. GLP-1 is a hormone involved in appetite, digestion, and blood-glucose regulation. Semaglutide acts on GLP-1 receptors: it can increase feelings of fullness, reduce appetite, slow stomach emptying, and support glucose-dependent insulin release. It is prescribed for chronic weight management alongside nutrition and physical-activity changes. Ozempic also contains semaglutide, but its approved uses and dosing are not identical to Wegovy’s. Use the product prescribed to you; do not switch or combine them without medical advice.

These effects can change how much you eat and drink. If you feel full sooner, skip meals, or experience nausea, vomiting, or diarrhea, you may take in less energy and fluid than usual. That can leave you feeling drained, light-headed, or less ready to exercise. Some people also report fatigue as a direct side effect, though tiredness can have several causes at once.

Why the titration period matters

Wegovy is generally started at a low dose and increased gradually. In the US schedule, dose increases usually occur every four weeks, with the maintenance dose reached after a series of steps. This titration period is intended to help the body adjust and may reduce gastrointestinal side effects. It does not guarantee that side effects will be absent, and people’s experiences differ.

Fatigue may be temporary, may come and go after an increase, or may persist for another reason. Do not increase, reduce, delay, or stop your dose on your own. If symptoms are affecting daily life, contact your prescriber: they can review the timing, your other medicines, and whether the treatment plan needs adjustment.

What do clinical trials say about fatigue?

In the STEP clinical-trial program, researchers studied semaglutide for weight management alongside lifestyle support. The trials found substantial average weight loss compared with placebo in the populations studied, while also documenting side effects. In STEP 1, for example, semaglutide 2.4 mg was compared with placebo in adults with overweight or obesity without diabetes, alongside lifestyle intervention. Gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation were among the most frequently reported adverse events.

Fatigue was also reported in Wegovy studies. In the US prescribing information for adults treated for weight reduction, fatigue occurred more often in the semaglutide group than in the placebo group (about 11% versus 5%). That finding supports fatigue as a possible side effect, but it cannot predict whether you will experience it, how severe it will be, or what is causing it in your particular case.

Randomized controlled trials (RCTs) are useful for comparing average outcomes between groups. They are less able to explain every individual experience: trial participants are monitored, may differ from people in routine care, and can have multiple contributors to tiredness. Study results are not a substitute for assessment, especially if fatigue is severe, worsening, or accompanied by other symptoms.

Common reasons for early fatigue

Alongside a possible medication effect, consider what has changed since treatment began. These are possibilities to discuss with your healthcare professional—not a way to diagnose yourself.

Eating less than your body needs: Appetite reduction can be helpful for weight management, but an abrupt or excessive drop in intake may make normal tasks and workouts feel harder. Dehydration: Nausea, vomiting, diarrhea, or simply drinking less can reduce fluid intake. This may contribute to weakness, headache, or dizziness. Changes in blood glucose: Semaglutide alone does not usually cause low blood sugar as often as some diabetes medicines, but risk can increase when it is combined with insulin or a sulfonylurea. Ask your diabetes team how to monitor and respond. Sleep, stress, or illness: Poor sleep, a viral infection, work pressure, and other common causes can overlap with the start of treatment. Other health conditions or medicines: Anemia, thyroid problems, mood changes, and medication effects are among the many issues a clinician may consider if fatigue continues.

What should you do if you feel tired?

Notice the pattern. Record when fatigue started, when you take your dose, whether it follows a dose increase, and how it affects sleep, work, and exercise. Note nausea, bowel changes, dizziness, and food or fluid intake too. Prioritize regular nourishment and fluids. If appetite is low, ask your prescriber or a registered dietitian for practical ways to meet your nutrition needs. Choose manageable meals and fluids you can tolerate; do not use extreme restriction to try to accelerate weight loss. Adjust training temporarily. If your usual session feels unusually difficult, reduce intensity or volume, take rest days, and avoid pushing through dizziness or marked weakness. Keep gentle movement if it feels comfortable. Your training capacity may vary during the titration period, and a short-term adjustment is not failure. Review your medicines with a professional. Tell your prescriber or pharmacist about all prescription medicines, supplements, and weight-loss products. If you use insulin or a sulfonylurea, ask for individualized blood-glucose guidance. Contact your prescriber if it persists or interferes with daily life. They can assess whether the symptom fits the expected side-effect pattern or needs investigation. Do not change your Wegovy dose without their guidance.

When to seek urgent medical advice

Get urgent help for severe or persistent symptoms, especially if you cannot keep fluids down, feel faint or confused, or have signs of significant dehydration. Seek prompt medical care for severe, ongoing abdominal pain—particularly pain that may spread to your back—or an allergic reaction such as trouble breathing or swelling of the face or throat. These symptoms need assessment rather than being assumed to be routine tiredness.

If you have diabetes, follow the plan your clinician has given you for low blood glucose. Symptoms glp-1 and resistance training such as sweating, shaking, confusion, or sudden weakness can be consistent with hypoglycemia, particularly when semaglutide is used with certain other diabetes medicines. Check your glucose if instructed and follow your individualized treatment plan.

Guidance, eligibility, and safe access

Eligibility depends on where you live, your health history, and the indication for treatment. In the US, Wegovy is prescribed for people who meet its approved criteria, which generally include adults with obesity or adults with overweight plus at least one weight-related condition; there are also specific indications for some adolescents and for certain cardiovascular-risk reduction settings. A clinician must determine whether it is appropriate for you.

NICE guidance in England recommends semaglutide for weight management only for eligible people within specialist weight-management services, alongside a reduced-calorie diet and increased physical activity. The guidance includes BMI and weight-related health criteria, with lower BMI thresholds for some ethnic groups. It also sets limits and review arrangements, including stopping treatment if a person has not lost at least 5% of their initial weight after six months on treatment. NHS access and local pathways can vary, and the criteria may be updated; check current NICE guidance and speak with your local service rather than relying on a general summary.

Be cautious about offers on online marketplaces or claims promoted through social media channels. Products may be counterfeit, incorrectly stored, or not authorized for sale. Avoid buying prescription semaglutide from unverified sources, and do not use a product unless it has been prescribed and supplied through a legitimate, regulated pathway. A pharmacist or prescriber can help you check a product and discuss safer options.

What to track with your healthcare team

What to track Why it may help Fatigue onset and severity Shows whether symptoms began with treatment or a dose change and whether they are improving. Food, fluids, and stomach symptoms May reveal whether reduced intake, vomiting, or diarrhea is contributing. Exercise response and recovery Helps distinguish a manageable temporary dip from a major change in training capacity. Blood-glucose readings, if advised Can be important for people with diabetes, particularly when using insulin or a sulfonylurea.

The bottom line

Yes, early fatigue can occur when starting Wegovy, and trial data show it is reported more often with semaglutide than with placebo. The titration period, reduced appetite, stomach side effects, hydration, blood glucose, sleep, and other health factors can all play a part. Mild tiredness may settle, but severe, persistent, or worsening fatigue deserves a conversation with your prescriber.

Use Wegovy only as prescribed, make sensible adjustments to exercise when needed, and seek professional advice before changing your dose or adding other weight-loss products. A clinician can help you pursue weight-management goals while protecting your health, energy, and day-to-day functioning.